Contract Pharma5h
Vanda & AnaptysBio Partner for the Development and Commercialization of Imsidolimab
Vanda expects to immediately begin preparing BLA and MAA applications for the U.S. and EU.
Vanda Pharmaceuticals and Anaptys Announce Exclusive Global License Agreement for Vanda to Develop and Commercialize Imsidolimab, an IL-36R Antagonist
Imsidolimab has successfully completed two global Phase 3 studies in Generalized Pustular PsoriasisVanda expects to immediately begin preparing ...
Vanda Pharmaceuticals and AnaptysBio to develop and market imsidolimab
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Zacks.com on MSN3d
Pharma Stock Roundup: SNY and RHHBY's Q4 Earnings & More
Sanofi SNY and Roche RHHBY announced their fourth-quarter and full-year 2024 results. Novo Nordisk’s NVO novel obesity ...
Tribune2424d
Commission’s $221.6m FTX claim to now drop below other creditors
# The Supreme Court yesterday approved the Securities Commission’s bid to relegate its $221.55m claim against FTX behind those of the insolvent crypto exchange’s clients and other victims.
The Nassau Guardian4d
Court approves subordination deal on SCB's $221.55M claim against FTX
The Securities Commission of The Bahamas (SCB) has assessed $221.55 million in regulatory penalties against FTX Digital ...
Cure Today5d
FDA Accepts sNDA for Welireg in Advanced Pheochromocytoma and Paraganglioma
The FDA has accepted a priority review sNDA for Welireg in adults and pediatric patients with advanced or metastatic pheochromocytoma and paraganglioma.
MRK's sNDA for Welireg in Rare Tumors Gets FDA's Priority Tag
The FDA accepts and grants priority review to Merck's sNDA for Welireg to treat advanced pheochromocytoma and paraganglioma.